Free Trial

Leap Therapeutics (LPTX) Competitors

Leap Therapeutics logo
$0.37 +0.01 (+2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$0.37 +0.00 (+0.99%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LPTX vs. DTIL, ABVC, ALGS, UNCY, ANL, RENB, KRON, VTVT, ATNM, and PDSB

Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), ABVC BioPharma (ABVC), Aligos Therapeutics (ALGS), Unicycive Therapeutics (UNCY), Adlai Nortye (ANL), Renovaro (RENB), Kronos Bio (KRON), vTv Therapeutics (VTVT), Actinium Pharmaceuticals (ATNM), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry.

Leap Therapeutics vs. Its Competitors

Leap Therapeutics (NASDAQ:LPTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.21
Precision BioSciences$68.70M0.81$7.17M-$2.01-2.49

30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 7.5% of Leap Therapeutics shares are held by company insiders. Comparatively, 4.5% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Precision BioSciences had 2 more articles in the media than Leap Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.67 beat Precision BioSciences' score of 0.29 indicating that Leap Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Leap Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Precision BioSciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Leap Therapeutics presently has a consensus target price of $3.38, suggesting a potential upside of 823.65%. Precision BioSciences has a consensus target price of $47.00, suggesting a potential upside of 840.00%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Leap Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Precision BioSciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Leap Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Leap TherapeuticsN/A -162.15% -120.05%
Precision BioSciences -42.99%-69.26%-29.30%

Leap Therapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Summary

Precision BioSciences beats Leap Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Leap Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LPTX vs. The Competition

MetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.80M$3.06B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E Ratio-0.2120.8627.9419.95
Price / SalesN/A246.06396.5882.68
Price / CashN/A41.9636.1958.45
Price / Book0.408.308.635.82
Net Income-$67.56M-$55.19M$3.24B$258.42M
7 Day Performance7.16%5.07%3.22%1.94%
1 Month Performance30.45%17.61%10.72%12.02%
1 Year Performance-82.68%7.03%34.94%20.80%

Leap Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LPTX
Leap Therapeutics
1.9494 of 5 stars
$0.37
+2.3%
$3.38
+823.6%
-84.1%$14.80MN/A-0.2140
DTIL
Precision BioSciences
4.1551 of 5 stars
$4.65
+0.9%
$47.00
+910.8%
-50.4%$51.12M$68.70M-2.31200Upcoming Earnings
ABVC
ABVC BioPharma
0.6761 of 5 stars
$3.52
+5.1%
N/A+287.6%$56.89M$510K-27.0830
ALGS
Aligos Therapeutics
3.7921 of 5 stars
$8.64
-5.7%
$70.00
+710.2%
-32.5%$56.01M$3.94M-0.4990News Coverage
Gap Down
UNCY
Unicycive Therapeutics
3.0258 of 5 stars
$4.50
+1.6%
$60.00
+1,233.3%
+15.8%$56M$680K-0.889
ANL
Adlai Nortye
1.4037 of 5 stars
$1.52
+1.3%
$9.00
+492.1%
-58.4%$55.35M$5M0.00127Positive News
Gap Down
RENB
Renovaro
2.2102 of 5 stars
$0.31
-2.8%
N/A-74.4%$54.54MN/A-0.4020News Coverage
Gap Down
KRON
Kronos Bio
N/A$0.88
+1.5%
$1.63
+84.7%
-35.8%$53.72M$9.85M-0.82100
VTVT
vTv Therapeutics
1.5991 of 5 stars
$16.55
+2.4%
$35.50
+114.5%
-31.7%$53.57M$1.02M-5.509Positive News
ATNM
Actinium Pharmaceuticals
2.7438 of 5 stars
$1.69
-1.2%
$4.00
+136.7%
N/A$52.72MN/A-1.2230News Coverage
PDSB
PDS Biotechnology
1.029 of 5 stars
$1.15
flat
$9.00
+682.6%
-70.4%$52.57MN/A-1.2220

Related Companies and Tools


This page (NASDAQ:LPTX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners